Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• RANKL inhibits macrophage proinflammatory Toll-like receptor 2 and 4 signaling and impairs killing of intracellular bacteria.

  PMID 42177796 · PMC13198865 · ImmunoHorizons · 2026 · 8 claims · 8 setups

  Full-text index only

  Prior RANKL exposure increases intracellular Salmonella Typhimurium (STm) burden in mouse and human macrophages

  bone bmdms raw-dual splenic bacterial viability sequencing

• Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.

  PMID 41494534 · PMC12866099 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  VPNS@P selectively accumulates in immune cells within atherosclerotic plaques (predominantly macrophages and monocytes, partly T and B cells) with minimal off-target uptake by non-immune vascular cells

  vpns@p cell-free raw264.7 bone-marrow-derived tem ros-scavenging cck-8

• MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

  PMID 16834459 · PMC1502153 · PLoS medicine · 2006 · 8 claims · 8 setups

  Full-text index only

  A somatic activating mutation in MPL (W515L, transmembrane domain) is present in 9% (4/45) of JAK2V617F-negative myelofibrosis (MF) patients

  granulocyte hapmap 32d balb sequencing genotyping proliferation